NCCN Task Force report: update on the management of patients with gastrointestinal stromal tumors.
暂无分享,去创建一个
C. Antonescu | G. Demetri | C. Raut | R. Maki | R. Riedel | R. DeMatteo | M. von Mehren | K. Ganjoo | S. Schuetze | J. Wayne | Hema M Sundar | M. Mehren | P. Pisters | J. Trent
[1] C. Mussi,et al. Post-imatinib surgery in advanced/metastatic GIST: is it worthwhile in all patients? , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.
[2] J. Plana,et al. Rare incidence of congestive heart failure in gastrointestinal stromal tumor and other sarcoma patients receiving imatinib mesylate , 2009, Cancer.
[3] Zhiyuan Wei,et al. Diagnosis and treatment of gastrointestinal stromal tumors , 2010 .
[4] E. Wardelmann,et al. Neoadjuvant imatinib and organ preservation in locally advanced gastrointestinal stromal tumors (GIST). , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[5] J. Manola,et al. Cytoreductive Surgery in Patients with Metastatic Gastrointestinal Stromal Tumor Treated with Sunitinib Malate , 2010, Annals of Surgical Oncology.
[6] M. Heinrich,et al. Insulin‐like growth factor 1 receptor expression in wild‐type GISTs: A potential novel therapeutic target , 2009, International journal of cancer.
[7] Xin Huang,et al. Electrocardiographic Characterization of the QTc Interval in Patients with Advanced Solid Tumors: Pharmacokinetic- Pharmacodynamic Evaluation of Sunitinib , 2009, Clinical Cancer Research.
[8] C. Antonescu,et al. Development and validation of a prognostic nomogram for recurrence-free survival after complete surgical resection of localised primary gastrointestinal stromal tumour: a retrospective analysis. , 2009, The Lancet. Oncology.
[9] G. Demetri,et al. Acute myeloid leukemia in patients with gastrointestinal stromal tumors treated with Gleevec , 2009, Leukemia & lymphoma.
[10] Narasimhan P. Agaram,et al. Mechanisms of Sunitinib Resistance in Gastrointestinal Stromal Tumors Harboring KITAY502-3ins Mutation: An In vitro Mutagenesis Screen for Drug Resistance , 2009, Clinical Cancer Research.
[11] G. Demetri,et al. Phase I Dose-Escalation and Pharmacokinetic Study of Dasatinib in Patients with Advanced Solid Tumors , 2009, Clinical Cancer Research.
[12] J. Blay,et al. A Phase I Study of Single-Agent Nilotinib or in Combination with Imatinib in Patients with Imatinib-Resistant Gastrointestinal Stromal Tumors , 2009, Clinical Cancer Research.
[13] H. Joensuu,et al. Nilotinib in the treatment of advanced gastrointestinal stromal tumours resistant to both imatinib and sunitinib. , 2009, European journal of cancer.
[14] J. Lasota,et al. DOG1 Antibody in the Differential Diagnosis of Gastrointestinal Stromal Tumors: A Study of 1840 Cases , 2009, The American journal of surgical pathology.
[15] Steven P. Gygi,et al. SDH5, a Gene Required for Flavination of Succinate Dehydrogenase, Is Mutated in Paraganglioma , 2009, Science.
[16] J. Blay,et al. Absence of progression as assessed by response evaluation criteria in solid tumors predicts survival in advanced GI stromal tumors treated with imatinib mesylate: the intergroup EORTC-ISG-AGITG phase III trial. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[17] S. Sleijfer,et al. Gastrointestinal stromal tumors II: medical oncology and tumor response assessment. , 2009, Seminars in oncology.
[18] G. Poston,et al. Diagnosis and multi-disciplinary management of hepatic metastases from gastrointestinal stromal tumour (GIST). , 2009, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.
[19] R. Stock,et al. Phase 1 study of concurrent sunitinib and image‐guided radiotherapy followed by maintenance sunitinib for patients with oligometastases , 2009, Cancer.
[20] G. Demetri,et al. Imatinib plasma levels are correlated with clinical benefit in patients with unresectable/metastatic gastrointestinal stromal tumors. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[21] J. Blay,et al. Clinical evaluation of continuous daily dosing of sunitinib malate in patients with advanced gastrointestinal stromal tumour after imatinib failure. , 2009, European journal of cancer.
[22] J. Carney,et al. The triad of paragangliomas, gastric stromal tumours and pulmonary chondromas (Carney triad), and the dyad of paragangliomas and gastric stromal sarcomas (Carney–Stratakis syndrome): molecular genetics and clinical implications , 2009, Journal of internal medicine.
[23] A. D. Van den Abbeele,et al. Sunitinib treatment in pediatric patients with advanced GIST following failure of imatinib , 2009, Pediatric blood & cancer.
[24] W. Brugge,et al. A guide for the diagnosis and management of gastrointestinal stromal cell tumors , 2009, Nature Reviews Gastroenterology &Hepatology.
[25] K. Lok,et al. Endosonographic surveillance of small gastrointestinal tumors originating from muscularis propria. , 2009, Journal of gastrointestinal and liver diseases : JGLD.
[26] M. Pantaleo,et al. Mechanisms of secondary resistance to tyrosine kinase inhibitors in gastrointestinal stromal tumours (Review). , 2009, Oncology reports.
[27] P. Martiat,et al. Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: the ADAGIO study. , 2009, Blood.
[28] L. Shen,et al. Adjuvant therapy with imatinib in gastrointestinal stromal tumor (GIST) patients with intermediate or high risk: Analysis from a single-center contrast study. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[29] B. Bui,et al. Sorafenib fourth-line treatment in imatinib-, sunitinib-, and nilotinib-resistant metastatic GIST: A retrospective analysis. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[30] J. Blay,et al. Time to secondary resistance (TSR) after interruption of imatinib: Updated results of the prospective French Sarcoma Group randomized phase III trial on long-term survival. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[31] D. Santini,et al. Evaluation of Ki-67 in gastrointestinal stromal tumor (GIST). , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[32] J. Soria,et al. Review Management of Hypertension in Angiogenesis Inhibitor-treated Patients , 2022 .
[33] S. Corsello,et al. Hypothyroidism related to tyrosine kinase inhibitors: an emerging toxic effect of targeted therapy , 2009, Nature Reviews Clinical Oncology.
[34] C. Antonescu,et al. Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial , 2009, The Lancet.
[35] C. Corless,et al. Monoclonal Antibody DOG1.1 Shows Higher Sensitivity Than KIT in the Diagnosis of Gastrointestinal Stromal Tumors, Including Unusual Subtypes , 2009, The American journal of surgical pathology.
[36] Yan Zhang,et al. KIT kinase mutants show unique mechanisms of drug resistance to imatinib and sunitinib in gastrointestinal stromal tumor patients , 2009, Proceedings of the National Academy of Sciences.
[37] Sanjay Gupta,et al. Gastrointestinal stromal tumor: role of interventional radiology in diagnosis and treatment. , 2009, Hematology/oncology clinics of North America.
[38] R. Pazdur,et al. Approval summary: imatinib mesylate in the treatment of metastatic and/or unresectable malignant gastrointestinal stromal tumors. , 2009, The oncologist.
[39] M. Robson,et al. Inherited predisposition to gastrointestinal stromal tumor. , 2009, Hematology/oncology clinics of North America.
[40] John O. Prior,et al. Early prediction of response to sunitinib after imatinib failure by 18F-fluorodeoxyglucose positron emission tomography in patients with gastrointestinal stromal tumor. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[41] G. Demetri,et al. Small molecule tyrosine kinase inhibitor and depression. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[42] K. Stergiopoulos,et al. Risk of hypertension and renal dysfunction with an angiogenesis inhibitor sunitinib: Systematic review and meta-analysis , 2009, Acta oncologica.
[43] M. Lacouture,et al. Risk of hand-foot skin reaction with the multitargeted kinase inhibitor sunitinib in patients with renal cell and non-renal cell carcinoma: a meta-analysis. , 2009, Clinical genitourinary cancer.
[44] G. Demetri,et al. Phase II trial of neoadjuvant/adjuvant imatinib mesylate (IM) for advanced primary and metastatic/recurrent operable gastrointestinal stromal tumor (GIST): Early results of RTOG 0132/ACRIN 6665 , 2009, Journal of surgical oncology.
[45] C. Antonescu,et al. Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[46] K. Owzar,et al. Correlation of kinase genotype and clinical outcome in the North American Intergroup Phase III Trial of imatinib mesylate for treatment of advanced gastrointestinal stromal tumor: CALGB 150105 Study by Cancer and Leukemia Group B and Southwest Oncology Group. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[47] P. Thall,et al. A Randomized, Phase II Study of Preoperative plus Postoperative Imatinib in GIST: Evidence of Rapid Radiographic Response and Temporal Induction of Tumor Cell Apoptosis , 2008, Annals of Surgical Oncology.
[48] A. Godwin,et al. The insulin-like growth factor system as a potential therapeutic target in gastrointestinal stromal tumors , 2008, Cell cycle.
[49] Narasimhan P. Agaram,et al. Novel V600E BRAF mutations in imatinib‐naive and imatinib‐resistant gastrointestinal stromal tumors , 2008, Genes, chromosomes & cancer.
[50] J. Fletcher,et al. Protein kinase C-θ regulates KIT expression and proliferation in gastrointestinal stromal tumors , 2008, Oncogene.
[51] P. Marynen,et al. Activity of Dasatinib, a Dual SRC/ABL Kinase Inhibitor, and IPI-504, a Heat Shock Protein 90 Inhibitor, against Gastrointestinal Stromal Tumor–Associated PDGFRAD842V Mutation , 2008, Clinical Cancer Research.
[52] J. Lasota,et al. Clinical significance of oncogenic KIT and PDGFRA mutations in gastrointestinal stromal tumours , 2008, Histopathology.
[53] J. Fletcher,et al. Heterogeneity of kinase inhibitor resistance mechanisms in GIST , 2008, The Journal of pathology.
[54] H. Yamaue,et al. Laparoscopic resection for gastrointestinal stromal tumors of the stomach. , 2008, American journal of surgery.
[55] Wei-Lien Wang,et al. Unlucky number 13? Differential effects of KIT exon 13 mutation in gastrointestinal stromal tumors , 2008, Molecular oncology.
[56] C. Mussi,et al. Therapeutic Consequences from Molecular Biology for Gastrointestinal Stromal Tumor Patients Affected by Neurofibromatosis Type 1 , 2008, Clinical Cancer Research.
[57] H. Chang,et al. Surgical intervention following imatinib treatment in patients with advanced gastrointestinal stromal tumors (GISTs) , 2008, Journal of surgical oncology.
[58] C. Braconi,et al. Insulin-like growth factor (IGF) 1 and 2 help to predict disease outcome in GIST patients. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.
[59] D. Flieder,et al. Insulin-like growth factor 1 receptor is a potential therapeutic target for gastrointestinal stromal tumors , 2008, Proceedings of the National Academy of Sciences.
[60] M. Kendrick,et al. Laparoscopic gastric gastrointestinal stromal tumor resection: the mayo clinic experience. , 2008, Archives of surgery.
[61] L. Terracciano,et al. Microscopic Gastrointestinal Stromal Tumors in Esophageal and Intestinal Surgical Resection Specimens: A Clinicopathologic, Immunohistochemical, and Molecular Study of 19 Lesions , 2008, The American journal of surgical pathology.
[62] E. Vokes,et al. Activity of sorafenib (SOR) in patients (pts) with imatinib (IM) and sunitinib (SU)-resistant (RES) gastrointestinal stromal tumors (GIST): A phase II trial of the University of Chicago Phase II Consortium , 2008 .
[63] Patrick Schöffski,et al. Novel statistical analysis of long-term survival to account for crossover in a phase III trial of sunitinib (SU) vs. placebo (PL) in advanced GIST after imatinib (IM) failure , 2008 .
[64] Narasimhan P. Agaram,et al. Molecular Characterization of Pediatric Gastrointestinal Stromal Tumors , 2008, Clinical Cancer Research.
[65] T. Buclin,et al. Relationship of imatinib-free plasma levels and target genotype with efficacy and tolerability , 2008, British Journal of Cancer.
[66] M. Pierotti,et al. PDGFRA Immunostaining Can Help in the Diagnosis of Gastrointestinal Stromal Tumors , 2008, The American journal of surgical pathology.
[67] C. Antonescu,et al. Clinicopathologic profile of gastrointestinal stromal tumors (GISTs) with primary KIT exon 13 or exon 17 mutations: a multicenter study on 54 cases , 2008, Modern Pathology.
[68] J. Fletcher,et al. Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[69] J. Crowley,et al. Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[70] C. Antonescu,et al. Tumor mitotic rate, size, and location independently predict recurrence after resection of primary gastrointestinal stromal tumor (GIST) , 2008, Cancer.
[71] Wei Zhang,et al. Clinical, histopathologic, molecular and therapeutic findings in a large kindred with gastrointestinal stromal tumor , 2008, International journal of cancer.
[72] Kevin S. Smith,et al. A Novel Monoclonal Antibody Against DOG1 is a Sensitive and Specific Marker for Gastrointestinal Stromal Tumors , 2008, The American journal of surgical pathology.
[73] S. Oudard,et al. Home blood-pressure monitoring in patients receiving sunitinib. , 2008, The New England journal of medicine.
[74] R. Chetty. Small and microscopically detected gastrointestinal stromal tumours: an overview , 2008, Pathology.
[75] J. Ellison,et al. Clinical and molecular genetics of patients with the Carney–Stratakis syndrome and germline mutations of the genes coding for the succinate dehydrogenase subunits SDHB, SDHC, and SDHD , 2008, European Journal of Human Genetics.
[76] David Zurakowski,et al. Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib , 2007, The Lancet.
[77] A. D. Van den Abbeele,et al. CT and PET: early prognostic indicators of response to imatinib mesylate in patients with gastrointestinal stromal tumor. , 2007, AJR. American journal of roentgenology.
[78] J. Fletcher,et al. Pediatric KIT wild-type and platelet-derived growth factor receptor alpha-wild-type gastrointestinal stromal tumors share KIT activation but not mechanisms of genetic progression with adult gastrointestinal stromal tumors. , 2007, Cancer research.
[79] W. Zhan. Efficacy and safety of adjuvant post-surgical therapy with imatinib in patients with high risk of relapsing GIST , 2007 .
[80] K. Owzar,et al. Comparison of two doses of imatinib for the treatment of unresectable or metastatic gastrointestinal stromal tumors (GIST): A meta-analyis based on 1,640 patients (pts) , 2007 .
[81] Haesun Choi,et al. We should desist using RECIST, at least in GIST. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[82] Haesun Choi,et al. Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[83] J. Blay,et al. Prospective multicentric randomized phase III study of imatinib in patients with advanced gastrointestinal stromal tumors comparing interruption versus continuation of treatment beyond 1 year: the French Sarcoma Group. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[84] P. Casali,et al. Surgery of Residual Disease Following Molecular-targeted Therapy With Imatinib Mesylate in Advanced/Metastatic GIST , 2007, Annals of surgery.
[85] C. Antonescu,et al. Results of Tyrosine Kinase Inhibitor Therapy Followed by Surgical Resection for Metastatic Gastrointestinal Stromal Tumor , 2007, Annals of surgery.
[86] A. Hartmann,et al. Minute Gastric Sclerosing Stromal Tumors (GIST Tumorlets) Are Common in Adults and Frequently Show c-KIT Mutations , 2007, The American journal of surgical pathology.
[87] Narasimhan P. Agaram,et al. Pathologic and Molecular Heterogeneity in Imatinib-Stable or Imatinib-Responsive Gastrointestinal Stromal Tumors , 2007, Clinical Cancer Research.
[88] J. Girones,et al. Population-based incidence and survival of gastrointestinal stromal tumours (GIST) in Girona, Spain. , 2007, European journal of cancer.
[89] J. Lasota,et al. Gastrointestinal stromal tumors: review on morphology, molecular pathology, prognosis, and differential diagnosis. , 2009, Archives of pathology & laboratory medicine.
[90] T. Nishida,et al. Surgical strategy for gastric gastrointestinal stromal tumors: laparoscopic vs. open resection , 2007, Surgical Endoscopy.
[91] N. Ge,et al. Endoscopic band ligation of small gastric stromal tumors and follow-up by endoscopic ultrasonography , 2007, Surgical Endoscopy.
[92] K. Ahrar,et al. Hepatic artery chemoembolization for 110 gastrointestinal stromal tumors , 2006, Cancer.
[93] T. Nakajima,et al. High incidence of microscopic gastrointestinal stromal tumors in the stomach. , 2006, Human pathology.
[94] M. Peterson,et al. Strong PDGFRA Positivity Is Seen in GISTs But Not in Other Intra-abdominal Mesenchymal Tumors: Immunohistochemical and Mutational Analyses , 2006, Applied immunohistochemistry & molecular morphology : AIMM.
[95] J. Desai,et al. Hypothyroidism after Sunitinib Treatment for Patients with Gastrointestinal Stromal Tumors , 2006, Annals of Internal Medicine.
[96] L. Chirieac,et al. Correlation of immunophenotype with progression‐free survival in patients with gastrointestinal stromal tumors treated with imatinib mesylate , 2006, Cancer.
[97] K. Hunt,et al. Surgical Resection of Gastrointestinal Stromal Tumors After Treatment with Imatinib , 2006, Annals of Surgical Oncology.
[98] J. Blay,et al. Pharmacokinetic-Pharmacodynamic Relationships of Imatinib and Its Main Metabolite in Patients with Advanced Gastrointestinal Stromal Tumors , 2006, Clinical Cancer Research.
[99] Xin Huang,et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial , 2006, The Lancet.
[100] J. Fletcher,et al. Molecular correlates of imatinib resistance in gastrointestinal stromal tumors. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[101] K. Brown,et al. Treatment of metastatic sarcoma to the liver with bland embolization , 2006, Cancer.
[102] P. Terrier,et al. Impact of Surgery on Advanced Gastrointestinal Stromal Tumors (GIST) in the Imatinib Era , 2006, Annals of Surgical Oncology.
[103] S. Owen,et al. Imatinib and altered bone and mineral metabolism. , 2006, The New England journal of medicine.
[104] H. Joensuu,et al. Imatinib and altered bone and mineral metabolism. , 2006, The New England journal of medicine.
[105] C. Park,et al. PKCθ expression in gastrointestinal stromal tumor , 2006, Modern Pathology.
[106] Brian Walters,et al. Cardiotoxicity of the cancer therapeutic agent imatinib mesylate , 2006, Nature Medicine.
[107] Y. Novitsky,et al. Long-term Outcomes of Laparoscopic Resection of Gastric Gastrointestinal Stromal Tumors , 2006, Annals of surgery.
[108] T. Pawlik,et al. Results of a single-center experience with resection and ablation for sarcoma metastatic to the liver. , 2006, Archives of surgery.
[109] J. Desai,et al. Surgical management of advanced gastrointestinal stromal tumors after treatment with targeted systemic therapy using kinase inhibitors. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[110] Glenn Heller,et al. Altered bone and mineral metabolism in patients receiving imatinib mesylate. , 2006, The New England journal of medicine.
[111] C. Antonescu. Gastrointestinal stromal tumor (GIST) pathogenesis, familial GIST, and animal models. , 2006, Seminars in diagnostic pathology.
[112] H. Joensuu,et al. Gastrointestinal stromal tumors with KIT exon 11 deletions are associated with poor prognosis. , 2006, Gastroenterology.
[113] J. Blay,et al. KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours. , 2006, European journal of cancer.
[114] J. Lasota,et al. Gastrointestinal stromal tumors: pathology and prognosis at different sites. , 2006, Seminars in diagnostic pathology.
[115] L. Koniaris,et al. Current incidence and outcomes of gastrointestinal mesenchymal tumors including gastrointestinal stromal tumors. , 2006, Journal of the American College of Surgeons.
[116] L. Sobin,et al. Gastrointestinal Stromal Tumors of the Jejunum and Ileum: A Clinicopathologic, Immunohistochemical, and Molecular Genetic Study of 906 Cases Before Imatinib With Long-term Follow-up , 2006, The American journal of surgical pathology.
[117] T. Kubota,et al. Operative indications for relatively small (2-5 cm) gastrointestinal stromal tumor of the stomach based on analysis of 60 operated cases. , 2006, Surgery.
[118] P. Nyckowski,et al. Surgical treatment of patients with initially inoperable and/or metastatic gastrointestinal stromal tumors (GIST) during therapy with imatinib mesylate , 2006, Journal of surgical oncology.
[119] E. Wardelmann,et al. Polyclonal Evolution of Multiple Secondary KIT Mutations in Gastrointestinal Stromal Tumors under Treatment with Imatinib Mesylate , 2006, Clinical Cancer Research.
[120] S. Steigen,et al. Trends in incidence and survival of mesenchymal neoplasm of the digestive tract within a defined population of Northern Norway , 2006, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.
[121] E. Glatstein,et al. Progression-free Survival in Gastrointestinal Stromal Tumours With High-dose Imatinib: Randomised Trial , 2006 .
[122] J. Stachura,et al. GISTs with PDGFRA exon 14 mutations represent subset of clinically favorable gastric tumors with epithelioid morphology , 2006, Laboratory Investigation.
[123] M. Boccadoro,et al. Corticosteroids can reverse severe imatinib-induced hepatotoxicity. , 2006, Haematologica.
[124] C. Bokemeyer,et al. Dasatinib (BMS-354825), a dual SRC/ABL kinase inhibitor, inhibits the kinase activity of wild-type, juxtamembrane, and activation loop mutant KIT isoforms associated with human malignancies. , 2006, Cancer research.
[125] R. Herings,et al. Incidence of gastrointestinal stromal tumours is underestimated: results of a nation-wide study. , 2005, European journal of cancer.
[126] G. Antoch,et al. Resection of residual disease in patients with metastatic gastrointestinal stromal tumors responding to treatment with imatinib , 2005, International journal of cancer.
[127] R. DeMatteo,et al. Gastrointestinal stromal tumor: 5 years later , 2005, Cancer.
[128] J. Jónasson,et al. Gastrointestinal stromal tumors in Iceland, 1990–2003: The Icelandic GIST study, a population‐based incidence and pathologic risk stratification study , 2005, International journal of cancer.
[129] L. Sobin,et al. Gastrointestinal Stromal Tumors of the Stomach in Children and Young Adults: A Clinicopathologic, Immunohistochemical, and Molecular Genetic Study of 44 Cases With Long-Term Follow-Up and Review of the Literature , 2005, The American journal of surgical pathology.
[130] A. Llombart‐Bosch,et al. Deletions affecting codons 557-558 of the c-KIT gene indicate a poor prognosis in patients with completely resected gastrointestinal stromal tumors: a study by the Spanish Group for Sarcoma Research (GEIS). , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[131] Markku Miettinen,et al. KIT (CD117): A Review on Expression in Normal and Neoplastic Tissues, and Mutations and Their Clinicopathologic Correlation , 2005, Applied immunohistochemistry & molecular morphology : AIMM.
[132] M. Heinrich,et al. PDGFRA mutations in gastrointestinal stromal tumors: frequency, spectrum and in vitro sensitivity to imatinib. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[133] L. Osterberg,et al. Adherence to medication. , 2005, The New England journal of medicine.
[134] J. Blay,et al. Outcome of patients with advanced gastro-intestinal stromal tumours crossing over to a daily imatinib dose of 800 mg after progression on 400 mg. , 2005, European journal of cancer.
[135] S. Hirota,et al. Pathophysiology, diagnosis, and treatment of gastrointestinal stromal tumors , 2005, Journal of Gastroenterology.
[136] A. D. Van den Abbeele,et al. Gastrointestinal stromal tumor: new nodule-within-a-mass pattern of recurrence after partial response to imatinib mesylate. , 2005, Radiology.
[137] C. Antonescu,et al. Acquired Resistance to Imatinib in Gastrointestinal Stromal Tumor Occurs Through Secondary Gene Mutation , 2005, Clinical Cancer Research.
[138] Mariël Brok,et al. Chronic imatinib mesylate exposure leads to reduced intracellular drug accumulation by induction of the ABCG2 (BCRP) and ABCB1 (MDR1) drug transport pumps , 2005, Cancer biology & therapy.
[139] M. Federico,et al. PDGFR expression in differential diagnosis between KIT‐negative gastrointestinal stromal tumours and other primary soft‐tissue tumours of the gastrointestinal tract , 2005, Histopathology.
[140] N. Socci,et al. Gastrointestinal Stromal Tumors in Children and Young Adults: A Clinicopathologic, Molecular, and Genomic Study of 15 Cases and Review of the Literature , 2005, Journal of pediatric hematology/oncology.
[141] B. Nilsson,et al. Gastrointestinal stromal tumors: The incidence, prevalence, clinical course, and prognostication in the preimatinib mesylate era , 2005, Cancer.
[142] P. Marynen,et al. Mechanisms of resistance to imatinib mesylate in gastrointestinal stromal tumors and activity of the PKC412 inhibitor against imatinib-resistant mutants. , 2005, Gastroenterology.
[143] C. Corless,et al. State-of-the Art Therapy for Gastrointestinal Stromal Tumors , 2005, Cancer investigation.
[144] L. Sobin,et al. Gastrointestinal Stromal Tumors of the Stomach: A Clinicopathologic, Immunohistochemical, and Molecular Genetic Study of 1765 Cases With Long-term Follow-up , 2005, The American journal of surgical pathology.
[145] H. El‐Serag,et al. The Epidemiology of Malignant Gastrointestinal Stromal Tumors: An Analysis of 1,458 Cases from 1992 to 2000 , 2005, The American Journal of Gastroenterology.
[146] ほか,et al. Imatinib Mesylate(STI 571)が著効した小腸Gastrointestinal Stromal Tumor術後腹腔内再発の1例 , 2005 .
[147] Haesun Choi. Critical issues in response evaluation on computed tomography: Lessons from the gastrointestinal stromal tumor model , 2005, Current oncology reports.
[148] Y. Otani,et al. Laparoscopic surgery for GIST: too soon to decide , 2005, Gastric Cancer.
[149] E. Pareja,et al. Combined liver transplantation plus imatinib for unresectable metastases of gastrointestinal stromal tumours. , 2004, European journal of gastroenterology & hepatology.
[150] Tina Hernandez-Boussard,et al. Gastrointestinal stromal tumors (GISTs) with KIT and PDGFRA mutations have distinct gene expression profiles , 2004, Oncogene.
[151] K. Nooter,et al. Pharmacokinetic Resistance to Imatinib Mesylate: Role of the ABC Drug Pumps ABCG2 (BCRP) and ABCB1 (MDR1) in the Oral Bioavailability of Imatinib , 2004, Cell cycle.
[152] Wei Zhang,et al. A Missense Mutation in KIT Kinase Domain 1 Correlates with Imatinib Resistance in Gastrointestinal Stromal Tumors , 2004, Cancer Research.
[153] J. Fletcher,et al. Protein Kinase C θ (PKCθ) Expression and Constitutive Activation in Gastrointestinal Stromal Tumors (GISTs) , 2004, Cancer Research.
[154] A. D. Van den Abbeele,et al. Effects of cessation of imatinib mesylate (IM) therapy in patients (pts) with IM-refractory gastrointestinal stromal tumors (GIST) as visualized by FDG-PET scanning. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[155] J. Fletcher,et al. KIT-Negative Gastrointestinal Stromal Tumors: Proof of Concept and Therapeutic Implications , 2004, The American journal of surgical pathology.
[156] L. Sobin,et al. A great majority of GISTs with PDGFRA mutations represent gastric tumors of low or no malignant potential , 2004, Laboratory Investigation.
[157] C. Ball,et al. The novel marker, DOG1, is expressed ubiquitously in gastrointestinal stromal tumors irrespective of KIT or PDGFRA mutation status. , 2004, The American journal of pathology.
[158] F. Guilhot. Indications for imatinib mesylate therapy and clinical management. , 2004, The oncologist.
[159] N. Socci,et al. Gene Expression in Gastrointestinal Stromal Tumors Is Distinguished by KIT Genotype and Anatomic Site , 2004, Clinical Cancer Research.
[160] Tae Won Kim,et al. Prognostic Significance of c-kit Mutation in Localized Gastrointestinal Stromal Tumors , 2004, Clinical Cancer Research.
[161] A. Hagemeijer,et al. Gastrointestinal stromal tumours (GISTs) negative for KIT (CD117 antigen) immunoreactivity , 2004, The Journal of pathology.
[162] M. van Glabbeke,et al. Use of c-KIT/PDGFRA mutational analysis to predict the clinical response to imatinib in patients with advanced gastrointestinal stromal tumours entered on phase I and II studies of the EORTC Soft Tissue and Bone Sarcoma Group. , 2004, European journal of cancer.
[163] R. Benjamin,et al. A two‐arm phase II study of temozolomide in patients with advanced gastrointestinal stromal tumors and other soft tissue sarcomas , 2003, Cancer.
[164] K. Hunt,et al. Is there a role for surgery in patients with "unresectable" cKIT+ gastrointestinal stromal tumors treated with imatinib mesylate? , 2003, American journal of surgery.
[165] A. D. Van den Abbeele,et al. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[166] S. Steigen,et al. Gastrointestinal Stromal Tumors with Internal Tandem Duplications in 3′ End of KIT Juxtamembrane Domain Occur Predominantly in Stomach and Generally Seem to Have a Favorable Course , 2003, Modern Pathology.
[167] S. Hirota,et al. Gain-of-function mutations of platelet-derived growth factor receptor alpha gene in gastrointestinal stromal tumors. , 2003, Gastroenterology.
[168] M. Ladanyi,et al. Association of KIT exon 9 mutations with nongastric primary site and aggressive behavior: KIT mutation analysis and clinical correlates of 120 gastrointestinal stromal tumors. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.
[169] William Stafford Noble,et al. Classification and subtype prediction of adult soft tissue sarcoma by functional genomics. , 2003, The American journal of pathology.
[170] B. Nilsson,et al. Neoadjuvant, adjuvant and palliative treatment of gastrointestinal stromal tumours (GIST) with imatinib: a centre-based study of 17 patients , 2003, British Journal of Cancer.
[171] D. Faigel,et al. GI stromal tumors. , 2003, Gastrointestinal endoscopy.
[172] Samuel Singer,et al. PDGFRA Activating Mutations in Gastrointestinal Stromal Tumors , 2003, Science.
[173] Y. Omuro,et al. [Gastrointestinal cancer]. , 2003, Nihon rinsho. Japanese journal of clinical medicine.
[174] J. Manola,et al. A phase II and pharmacokinetic study of ecteinascidin 743 in patients with gastrointestinal stromal tumors. , 2002, The oncologist.
[175] R. Pazdur,et al. Approval summary: imatinib mesylate in the treatment of metastatic and/or unresectable malignant gastrointestinal stromal tumors. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.
[176] J. Fletcher,et al. Prognostic value of KIT mutation type, mitotic activity, and histologic subtype in gastrointestinal stromal tumors. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[177] A. D. Van den Abbeele,et al. Use of positron emission tomography in oncology and its potential role to assess response to imatinib mesylate therapy in gastrointestinal stromal tumors (GISTs). , 2002, European journal of cancer.
[178] A. D. Van den Abbeele,et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. , 2002, The New England journal of medicine.
[179] L. Sobin,et al. Diagnosis of gastrointestinal stromal tumors: A consensus approach. , 2002, Human pathology.
[180] M. Heinrich,et al. KIT mutations are common in incidental gastrointestinal stromal tumors one centimeter or less in size. , 2002, The American journal of pathology.
[181] D. Botstein,et al. For Personal Use. Only Reproduce with Permission from the Lancet Publishing Group , 2022 .
[182] J. Buckner,et al. Contrast of Response to Dacarbazine, Mitomycin, Doxorubicin, and Cisplatin (DMAP) Plus GM-CSF Between Patients with Advanced Malignant Gastrointestinal Stromal Tumors and Patients with Other Advanced Leiomyosarcomas , 2002, Cancer investigation.
[183] C. J. Chen,et al. KIT activation is a ubiquitous feature of gastrointestinal stromal tumors. , 2001, Cancer research.
[184] Sigrid Stroobants,et al. Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study , 2001, The Lancet.
[185] T. Jacks,et al. STI571 inactivation of the gastrointestinal stromal tumor c-KIT oncoprotein: biological and clinical implications , 2001, Oncogene.
[186] D. Tuveson,et al. Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. , 2001, The New England journal of medicine.
[187] S. Hirota,et al. Biological and clinical review of stromal tumors in the gastrointestinal tract. , 2000, Histology and histopathology.
[188] L. Sobin,et al. Immunohistochemical Spectrum of GISTs at Different Sites and Their Differential Diagnosis with a Reference to CD117 (KIT) , 2000, Modern Pathology.
[189] B. Druker,et al. Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors. , 2000, The Journal of pharmacology and experimental therapeutics.
[190] B. Druker,et al. Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor. , 2000, Blood.
[191] Robert H Lyles,et al. Extragastrointestinal (Soft Tissue) Stromal Tumors: An Analysis of 48 Cases with Emphasis on Histologic Predictors of Outcome , 2000, Modern Pathology.
[192] R. DeMatteo,et al. Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival. , 2000, Annals of surgery.
[193] J. Lasota,et al. Gastrointestinal stromal tumors – definition, clinical, histological, immunohistochemical, and molecular genetic features and differential diagnosis , 2000, Virchows Archiv.
[194] K. Herholz,et al. Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group. , 1999, European journal of cancer.
[195] Edvardsson,et al. Expression of c‐kit (CD117) and Ki67 provides information about the possible cell of origin and clinical course of gastrointestinal stromal tumours , 1999, Histopathology.
[196] Jürg Zimmermann,et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr–Abl positive cells , 1996, Nature Medicine.
[197] L. Sobin,et al. Gastrointestinal cancer , 1995, Cancer.
[198] D. Coit,et al. Lymph Node Metastasis From Soft Tissue Sarcoma in Adults Analysis of Data From a Prospective Database of 1772 Sarcoma Patients , 1993, Annals of surgery.
[199] E. Atkinson,et al. Prognostic factors influencing survival in gastrointestinal leiomyosarcomas. Implications for surgical management and staging. , 1992, Annals of surgery.
[200] Bob Margulies,et al. Task force report , 1991 .
[201] G. Parker,et al. Gastrointestinal sarcomas. Analysis of prognostic factors. , 1987, Annals of surgery.
[202] O. Beahrs,et al. Leiomyosarcoma of the small and large bowel , 1978, Cancer.
[203] C. Newton. Comments and Suggestions , 1929 .